CVSI - CV Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0456
-0.0024 (-5.00%)
At close: 03:41PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.0480
Open0.0440
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0440 - 0.0480
52 Week Range0.0300 - 0.0700
Volume75,950
Avg. Volume150,225
Market Cap6.936M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateAug 14, 2023 - Aug 18, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CVSI

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • PR Newswire

    CV Sciences to Participate in LD Micro Invitational Conference

    CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced that Joseph Dowling, its Chief Executive Officer, will present at the LD Micro Invitational Conference in Los Angeles, California on June 7, 2023. This prominent investor conference showcases companies to micro-cap investors as they search for the next generation

  • PR Newswire

    CV Sciences, Inc. Reports First Quarter 2023 Financial Results

    CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2023.

  • PR Newswire

    CV SCIENCES, INC. TO ANNOUNCE FIRST QUARTER 2023 RESULTS ON MAY 15, 2023

    CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the first quarter ended March 31, 2023, before the stock market opens on Monday, May 15, 2023. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that

  • PR Newswire

    CV Sciences, Inc. Introduces New THC Offering

    CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced the launch of +PlusCBD™Reserve Collection Extra Gummies, the latest addition to the Company's popular +PlusCBD product line.

  • PR Newswire

    CV Sciences, Inc. Reports Fiscal Year-End 2022 Financial Results

    CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2022.

  • PR Newswire

    CV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2022 RESULTS ON MARCH 29, 2023

    CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the year and fourth quarter ended December 31, 2022, before the stock market opens on Wednesday, March 29, 2023. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m.

  • PR Newswire

    CV Sciences Receives Formal Notice of Patent Issuance from Japan Patent Office for Formulations Containing Cannabidiol (CBD) and Nicotine for Treating Smokeless Tobacco Addiction

    CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced that recently the Company received its formal Certificate of Grant from the Japan Patent Office (JPO) for its patent application 7216697.

  • PR Newswire

    CV Sciences, Inc. Launches New Line of THC-Free Gummies and Softgels

    CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced the launch of +PlusCBD™Daily Balance THC-Free Gummies and Softgels. These new additions to the +PlusCBD™ product portfolio are now available for purchase at +PlusCBD.

  • PR Newswire

    CV Sciences, Inc. Launches 30-Count of Popular +PlusCBD™ Reserve Collection Softgels

    CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced the launch of their popular +PlusCBD™ Reserve Collection Softgels in a 30-count bottle. This new offering will be available on +PlusCBD's' website on Thursday, Jan. 19.

  • PR Newswire

    CV Sciences, Inc. Reports Third Quarter 2022 Financial Results

    CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended September 30, 2022.

  • PR Newswire

    CV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2022 RESULTS ON NOVEMBER 14, 2022

    CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the third quarter ended September 30, 2022, before the stock market opens on Monday, November 14, 2022. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day.

  • PR Newswire

    CV Sciences, Inc. Extinguishes Convertible Debt

    CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, announced today that CV Sciences extinguished its entire outstanding convertible debt.

  • PR Newswire

    CV Sciences, Inc. Announces Launch of PlusCBD™ Reserve Collection Softgels

    CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced the launch of +PlusCBD™Reserve Collection Softgels to support stress relief and relaxation. The product will be available on +PlusCBD's' website on August 15, 2022.

  • PR Newswire

    CV Sciences, Inc. Reports Second Quarter 2022 Financial Results

    CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2022.